Servier Exercises the Exclusive Worldwide License Option of

CTA1 approval by the ANSM2 and the EC3 of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment in Parkinson's

Related Keywords

Paris , France General , France , French , Ross Jeggo , Arthur Rouill , Mathilde Bohin , Philippe Genne , Sonia Marques , Jan Hoflack , Instagram , Linkedin , Twitter , Ethics Committee , Facebook , Servier Group , Oncodesign Precision Medicine , Leucine Rich Repeat Kinase , Chief Scientific Officer , Managing Director , Global Head , Immuno Inflammation Therapeutic Area , Precision Medicine , Trial Application , National Agency , Chief Executive Officer , Servier , Exercises , Exclusive , Orldwide , License , Option , Their , Collaboration , Program , Ith , Oncodesign , Precision , Medicine , Parkinson , Disease ,